DENSITY | LEADERSHIP | PUBLIcations

Pharmaceutical pipeline

Amorphical is leveraging its proprietary Amorphous Calcium Carbonate to develop a pipeline of therapeutics for diseases where previous scientific studies have shown some correlation with blood calcium levels. This includes investigational programs in hypoparathyroidism, solid tumor-related bone metastasis and other calcium-related disorders.

Amorphical is currently conducting clinical studies with leading medical centers in Israel.

Based on the company’s preclinical and clinical findings, we believe ACC can function both as monotherapy as well as in combination with other medicinal products to produce innovative treatment modalities for a wide range of calcium-related diseases.